These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 7174561)

  • 1. The effects of nutrient limitation and growth rate in the chemostat on the immunogenicity of Vibrio cholerae.
    Green JA
    J Appl Bacteriol; 1982 Aug; 53(1):81-6. PubMed ID: 7174561
    [No Abstract]   [Full Text] [Related]  

  • 2. Persistence in the mouse gut as an important factor in oral immunogenicity of strains of V. cholerae.
    Bloom L; Rowley D
    Aust J Exp Biol Med Sci; 1979 Jun; 57(3):325-33. PubMed ID: 533484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunisation against cholera with a Ty21a-cholera hybrid.
    La Brooy JT; Forrest B; Bartholomeusz C
    Ann Sclavo Collana Monogr; 1986; 3(1-2):143-7. PubMed ID: 3426872
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effect of Vibrio cholerae toxoid on the levels of antibodies of the IgG, IgA and IgM classes in rabbits].
    Aleksandrowicz J; Kudelski Z
    Med Dosw Mikrobiol; 1986; 38(1):15-22. PubMed ID: 3713366
    [No Abstract]   [Full Text] [Related]  

  • 5. Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.
    Liao J; Gibson JA; Pickering BS; Watnick PI
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29875145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraduodenal inoculation of adult rabbits for evaluating the immunogenicity of genetically attenuated Vibrio cholerae strains.
    García Imia L; Oliva Hernández R; Cedré Marrero B; Valmaseda Pérez T; García Sánchez H; Talavera Coronel A; Pérez Quiñoy JL; Sierra González G
    Lab Anim Sci; 1998 Oct; 48(5):538-41. PubMed ID: 10090073
    [No Abstract]   [Full Text] [Related]  

  • 7. Prophylactic significance of the nonlipopolysaccharide antigens of Vibrio cholerae.
    Attridge SR; Rowley D
    J Infect Dis; 1983 Nov; 148(5):931-9. PubMed ID: 6195273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and protective capacity of inactivated "vibrio cholerae" whole cell vaccines.
    Cryz SJ; Fürer E; Germanier R
    Dev Biol Stand; 1983; 53():67-72. PubMed ID: 6873478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactogenicity and immunogenicity of oral cholera vaccine in Thai volunteers.
    Migasena S; Pitisuttitham P; Supanaranond W; Desakorn V; Prayurahong B; Suntharasamai P
    Southeast Asian J Trop Med Public Health; 1988 Sep; 19(3):423-8. PubMed ID: 3217824
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunogenicity of Vibrio cholerae O1 fimbriae in animal and human cholera.
    Ehara M; Ichinose Y; Iwami M; Utsunomiya A; Shimodori S; Kangethe SK; Neves BC; Supawat K; Nakamura S
    Microbiol Immunol; 1993; 37(9):679-88. PubMed ID: 7505875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of a candidate live oral typhoid/cholera hybrid vaccine in humans.
    Forrest BD; LaBrooy JT; Attridge SR; Boehm G; Beyer L; Morona R; Shearman DJ; Rowley D
    J Infect Dis; 1989 Jan; 159(1):145-6. PubMed ID: 2909633
    [No Abstract]   [Full Text] [Related]  

  • 12. Cumulative protective efficacy of rZot and rAce combination in challenge experiments with wild type Vibrio cholerae in mouse model.
    Anvari S; Najar-Peerayeh S; Behmanesh M; Bakhshi B
    Hum Vaccin Immunother; 2018; 14(9):2323-2328. PubMed ID: 29852089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of revaccination in persons inoculated primarily with whole-cell and toxoid cholera vaccines].
    Kiseleva IE; Domaradskiĭ IV; Erokhin EP; Kirdeev VK; Kiseleva VI
    Zh Mikrobiol Epidemiol Immunobiol; 1974 Jun; 51(6):64-7. PubMed ID: 4409388
    [No Abstract]   [Full Text] [Related]  

  • 14. Local immune response in mice to Vibrio cholerae.
    Bloom LD; Rowley D
    Aust J Exp Biol Med Sci; 1979 Jun; 57(3):313-23. PubMed ID: 394733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corresponding type-specificity of vibriocidal and agglutinating activities of Vibrio cholerae antisera: relevance to vaccine immunogenicity.
    Preston NW
    Epidemiol Infect; 1993 Jun; 110(3):489-97. PubMed ID: 8519314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and immunogenicity of conjugate based on hydrazine-treated lipopolysaccharide antigen of Vibrio cholerae O139.
    Fleischhackerová A; Farkaš P; Cížová A; Bystrický S
    Biosci Biotechnol Biochem; 2014; 78(11):1817-24. PubMed ID: 25070088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of an engineered bivalent vaccine strain consisting of Vibrio cholerae CT-B and LPS-O antigens.
    Yu X; Ma Q
    Chin J Biotechnol; 1994; 10(4):225-32. PubMed ID: 7780018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [An update on cholera infection].
    Israil A
    Bacteriol Virusol Parazitol Epidemiol; 1998; 43(3):185-94. PubMed ID: 9932009
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial Commentary: Resurrecting a Live Oral Cholera Vaccine.
    Harris JB
    Clin Infect Dis; 2016 Jun; 62(11):1336-7. PubMed ID: 27001802
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of enteric-coated tablets as a whole cell inactivated vaccine candidate against Vibrio cholerae.
    Fernández S; Año G; Castaño J; Pino Y; Uribarri E; Riverón LA; Cedré B; Valmaseda T; Falero G; Pérez JL; Infante JF; García LG; Solís RL; Sierra G; Talavera A
    Travel Med Infect Dis; 2013; 11(2):103-9. PubMed ID: 23492079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.